Saudi Arabia has shut down half of its oil production after drones attacked the world's largest oil processing facility in the kingdom.Marketsread more
Yemen's Houthi rebels have claimed responsibility for the attacks, which created a huge fire at a processor essential to global energy supplies.Politicsread more
Oil prices are expected to jump as much as $10 per barrel after a coordinated drone strike hit Saudi Arabia's largest oil field, forcing the kingdom to cut its oil output in...Marketsread more
Trusii's hydrogen water machines were supposed to help users with their health problems, but customers claim the company is involved in a giant scam.Technologyread more
The decoupling of the world's two weightiest economies seems as inescapable as its extent and global impact remains incalculable.Politicsread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
BlackBerry has reinvented itself to become a leader in securing mobile communications and in embedded communications. Next year it plans to roll out new products. CEO John...Evolveread more
Trailers have become a cult phenomenon. Even short teasers that reveal little about the plot of the upcoming film are headline-worthy. Blogs and forums have become devoted...Entertainmentread more
Thanks to the performance of Beyond Meat, investors who focus on venture-backed tech IPOs have done well this year despite some notable disappointments.Technologyread more
Software company Intuit, maker of tax helper TurboTax, is in its eleventh year of stock gains and up 36% this year.Investingread more
CNBC did a deep dive through the most recent Wall Street research to find stocks with upside potential.Marketsread more
June 3 (Reuters) - An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday.
Out of 10 heavily pre-treated lung cancer patients given the oral drug AMG510 daily, five had tumors shrink in size by at least 50%, including one with no evidence of the malignancy.
The disease was stabilized in another four patients, while the cancer progressed in one. Half of the evaluated patients had received the 960-milligram highest dose of AMG510 being tested in the dose-ranging study.
No serious side effects were reported in data presented in Chicago at the American Society of Clinical Oncology meeting.
Wall Street has taken a keen interest in the Amgen drug that could become the first approved medicine targeting a mutated form of a gene known as KRAS - one of the most common mutations found in non-small cell lung cancer (NSCLC).
NSCLC accounts for up to 85 percent of lung cancers, by far the leading cause of cancer death among men and women, according to the American Cancer Society.
Dr. Marwan Fakih, co-director of the gastrointestinal cancer program at City of Hope in Duarte, California, who led the study, noted the mild side effect profile compared with treatments like chemotherapy.
"Patients say they don't know they are even taking anything," he said in a phone interview.
The targeted mutation, KRASG12C, occurs in around 13% of NSCLC cases, as well as 3-5% of colorectal cancers and up to 2%of other solid tumor cancers, including pancreatic.
The trial also enrolled patients with colorectal cancer and cancer of the appendix.
Of 18 colorectal cancer patients evaluated by researchers, 13 achieved stable disease. Most were treated with the two lowest tested doses - 180mg and 360mg.
The 960mg dose is most likely to be used in future trials, Amgen said.
AMG510 is part of a growing trend of precision medicines that target gene mutations driving cancer regardless of which organ the disease originated.
"In principle, this drug has the potential to be effective in any patient with the KRAS mutation," Elliott Levy, Amgen's head of global development, said in an interview.
Other companies, such as Mirati Therapeutics Inc, are also developing drugs that target KRAS mutations, but Amgen's could be first to market.
"We have a plan to advance the drug rapidly through what would potentially be registrational studies," Levy said.
The U.S. Food and Drug Administration has granted orphan status to AMG510 for KRASG12C-positive NSCLC and colorectal cancers. The designation brings a longer exclusivity period.
Amgen has also begun testing AMG510 in combination with Merck & Co's cancer immunotherapy Keytruda, which currently dominates the advanced lung cancer market. (Reporting By Deena Beasley Editing by Bill Berkrot)